SPY303.79-0.53 -0.17%
DIA253.56-0.73 -0.29%
IXIC9,487.24-2.64 -0.03%

Ocular Therapeutix Says Public Offering Of 8.18M Common Shares Priced At $5.50/Share

  BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and

Benzinga · 05/20/2020 11:33

 

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 8,181,819 shares of its common stock at a public offering price of $5.50 per share for gross proceeds of approximately $45 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to an additional 1,227,272 shares in the public offering on the same terms and conditions. All of the shares in the offering are to be sold by the Company. The offering is expected to close on or about May 22, 2020, subject to the satisfaction of customary closing conditions.